Madan Jagasia

Company: Obsidian Therapeutics

Job title: Chief Executive Officer

Seminars:

Rational Engineering of TIL with Membrane-Bound IL15 to Optimize Expansion, Persistence, Safety, & Efficacy of TIL Cell Therapy for Solid Tumors 3:30 pm

Evaluating the design of T-cells to utilize IL15 Key advantages of membrane bound IL15 over IL2 Clinical data on effects of IL15 and its safety characterizationRead more

day: Conference Day One

Industry Leaders Fireside Chat: Challenges & Opportunities in Expanding Beyond Melanoma 8:30 am

What is the current state on developing TILs for indications beyond melanoma? What are key hurdles that must be overcome to apply TILs to more diverse indications? How do we evaluate what indications are most suitable to target with TILs? What are some key opportunities and breakthroughs in applying TILs to uncharted indications?Read more

day: Conference Day One